BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) — Market Cap & Net Worth
Market Cap & Net Worth: BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) has a market capitalization of $381.31 Million ($381.31 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13734 globally and #3303 in its home market, demonstrating a -46.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BridgeBio Oncology Therapeutics, Inc.'s stock price $4.76 by its total outstanding shares 80107104 (80.11 Million). Also see BBOT total assets for a full breakdown of the balance sheet.
BridgeBio Oncology Therapeutics, Inc. Market Cap History: 2025 to 2026
BridgeBio Oncology Therapeutics, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $1.00 Billion to $381.31 Million (0.00% CAGR). Also see cash efficiency ratio of BridgeBio Oncology Therapeutics, Inc. for how efficiently the company converts equity into cash flow.
BridgeBio Oncology Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BridgeBio Oncology Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of BridgeBio Oncology Therapeutics, Inc. for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BBOT by Market Capitalization
Companies near BridgeBio Oncology Therapeutics, Inc. in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of BridgeBio Oncology Therapeutics, Inc. to assess the quality of the company's equity after excluding intangible assets.
Key companies related to BridgeBio Oncology Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
BridgeBio Oncology Therapeutics, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, BridgeBio Oncology Therapeutics, Inc.'s market cap moved from $1.00 Billion to $ 381.31 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $381.31 Million | -61.98% |
| 2025 | $1.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of BridgeBio Oncology Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $381.31 Million USD |
| MoneyControl | $381.31 Million USD |
| MarketWatch | $381.31 Million USD |
| marketcap.company | $381.31 Million USD |
| Reuters | $381.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients… Read more